Loading...
•
Sep 30, 2021
OPKO Health Q3 2021 Earnings Report
Estimated Revenue:$302M
-19.3% YoY
Estimated EPS:-$0.01
125.0% YoY
Key Takeaways
OPKO Health reported a decrease in consolidated total revenues to $385.8 million compared to $428.1 million for the same period in 2020. However, operating income increased by 72% to $37.8 million, and net income was $28.7 million, or $0.04 per diluted share.
Health Canada approved NGENLA™ for pediatric growth hormone deficiency.
BioReference Laboratories processed approximately 2.2 million COVID-19 PCR tests.
BRL acquired the U.S. Ariosa centralized laboratory prenatal testing business from Roche.
Completed enrollment in Phase 2 trial evaluating RAYALDEE® as a treatment for symptomatic COVID-19 outpatients.
Revenue by Segment
Forward Guidance
OPKO Health's global regulatory applications for somatrogon are advancing, with action dates expected in the U.S., Europe, and Japan during the first half of 2022.
Loading...
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...